Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David John Kuter, M.D., Dr.Phil.

Co-Author

Back to Details
This page shows the publications co-authored by David Kuter and Hanny Al-Samkari.
David Kuter
Connection Strength
14.274
Hanny Al-Samkari
  1. A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica. 2021 04 01; 106(4):1148-1157.
    View in: PubMed
    Score: 0.929
  2. The role of romiplostim for pediatric patients with immune thrombocytopenia. Ther Adv Hematol. 2020; 11:2040620720912992.
    View in: PubMed
    Score: 0.871
  3. A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. Blood Adv. 2020 01 14; 4(1):9-18.
    View in: PubMed
    Score: 0.854
  4. Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment. Semin Thromb Hemost. 2020 Apr; 46(3):275-288.
    View in: PubMed
    Score: 0.849
  5. Lactate dehydrogenase is elevated in immune thrombocytopenia and inversely correlates with platelet count. Br J Haematol. 2019 11; 187(3):e61-e64.
    View in: PubMed
    Score: 0.833
  6. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol. 2019; 10:2040620719841735.
    View in: PubMed
    Score: 0.810
  7. Recurrence of Acute Intermittent Porphyria After Liver Transplantation. Ann Intern Med. 2019 06 18; 170(12):904-905.
    View in: PubMed
    Score: 0.800
  8. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim. Ann Hematol. 2019 Mar; 98(3):581-588.
    View in: PubMed
    Score: 0.788
  9. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. J Intern Med. 2019 02; 285(2):223-231.
    View in: PubMed
    Score: 0.782
  10. Infections and vaccination in hereditary hemorrhagic telangiectasia: microbiological evidence-based considerations. Haematologica. 2018 10; 103(10):e492-e495.
    View in: PubMed
    Score: 0.781
  11. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. Am J Hematol. 2018 12; 93(12):1501-1508.
    View in: PubMed
    Score: 0.780
  12. An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. Br J Clin Pharmacol. 2018 11; 84(11):2673-2677.
    View in: PubMed
    Score: 0.774
  13. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia. Br J Haematol. 2018 10; 183(2):168.
    View in: PubMed
    Score: 0.768
  14. Romiplostim for the management of perioperative thrombocytopenia. Br J Haematol. 2018 07; 182(1):106-113.
    View in: PubMed
    Score: 0.761
  15. The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. Haematologica. 2018 04; 103(4):e169-e172.
    View in: PubMed
    Score: 0.739
  16. Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia. Am J Hematol. 2021 12 01; 96(12):1563-1568.
    View in: PubMed
    Score: 0.239
  17. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. Haematologica. 2021 08 01; 106(8):2161-2169.
    View in: PubMed
    Score: 0.238
  18. An evaluation of avatrombopag for the treatment of thrombocytopenia. Expert Opin Pharmacother. 2021 Feb; 22(3):273-280.
    View in: PubMed
    Score: 0.226
  19. Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID-19). Am J Hematol. 2020 12; 95(12):1479-1485.
    View in: PubMed
    Score: 0.223
  20. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020 07 23; 136(4):489-500.
    View in: PubMed
    Score: 0.221
  21. Characterization of the rate, predictors, and thrombotic complications of thrombocytosis in iron deficiency anemia. Am J Hematol. 2020 Jul 03.
    View in: PubMed
    Score: 0.221
  22. Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features. Res Pract Thromb Haemost. 2020 Jul; 4(5):807-812.
    View in: PubMed
    Score: 0.220
  23. Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance. Blood Adv. 2019 11 26; 3(22):3515-3521.
    View in: PubMed
    Score: 0.212
  24. Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective. Haematologica. 2018 09; 103(9):1433-1443.
    View in: PubMed
    Score: 0.191
  25. SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. Blood. 2022 03 10; 139(10):1564-1574.
    View in: PubMed
    Score: 0.062
  26. Ammonia Predicts Hepatic Involvement and Pulmonary Hypertension in Patients With Hereditary Hemorrhagic Telangiectasia. Clin Transl Gastroenterol. 2020 01; 11(1):e00118.
    View in: PubMed
    Score: 0.053
  27. Perioperative thrombocytopenia: evidence, evaluation, and emerging therapies. Br J Anaesth. 2019 Jan; 122(1):19-31.
    View in: PubMed
    Score: 0.049
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.